YARROW BIOSCIENCE, INC. Business Acquisition, Pro Forma Net Income (Loss)
YARROW BIOSCIENCE, INC. (YARW) reported Business Acquisition, Pro Forma Net Income (Loss) of -$252.95 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2022-03-17
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$22.96M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-09-30 was -$24.91M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-06-30 was -$167.44M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for the quarter ending 2020-03-31 was -$37.64M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for fiscal 2020 was -$252.95M.
- YARROW BIOSCIENCE, INC. business acquisition, pro forma net income (loss) for fiscal 2019 was -$161.97M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$22.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$47.87M derived: sum of 2 quarters · filed 2022-03-17 | -$215.31M derived: sum of 3 quarters · filed 2022-03-17 | -$252.95M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$24.91M 10-Q · filed 2021-11-10 | -$192.35M derived: sum of 2 quarters · filed 2021-11-10 | -$229.99M 10-Q · filed 2021-11-10 | -$282.40M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$167.44M 10-Q · filed 2021-08-12 | -$205.08M 10-Q · filed 2021-08-12 | -$257.49M derived: sum of 3 quarters · filed 2021-08-12 | -$297.50M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$37.64M 10-Q · filed 2021-05-06 | -$90.05M derived: sum of 2 quarters · filed 2021-05-06 | -$130.06M derived: sum of 3 quarters · filed 2021-05-06 | -$165.53M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$52.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$92.42M derived: sum of 2 quarters · filed 2021-03-04 | -$127.89M derived: sum of 3 quarters · filed 2021-03-04 | -$161.97M 10-K · filed 2021-03-04 |
| 2019-09-30 | -$40.02M 10-Q · filed 2020-11-05 | -$75.49M derived: sum of 2 quarters · filed 2020-11-05 | -$109.56M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$35.47M 10-Q · filed 2020-08-06 | -$69.55M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | -$34.08M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |